Skip to main content

Day: January 5, 2021

Construction contract in Estonia (concrete works of Tehnopol 3 in Tallinn)

On 5 January 2021, AS Merko Ehitus Eesti, part of AS Merko Ehitus group, and OÜ Astlanda Ehitus entered into a contract for conducting concrete works of Tehnopol office building and parking house at Mäealuse 2/4, Tallinn.The contract includes construction of concrete structures of Tehnopol 3 office building with one underground and eight above ground floors and a parking house located at Tehnopol science and business campus in Tallinn Mustamäe district.The contract value is approximately EUR 3.85 million, plus value added tax. The works are scheduled to be completed in November 2021.AS Merko Ehitus Eesti (merko.ee) is Estonian leading construction company, which offers construction services in general construction, civil engineering, road, electrical and residential construction.Additional information: AS Merko Ehitus Eesti Head of Concrete...

Continue reading

Ehitusleping Eestis (Tehnopol 3 betoonitööd Tallinnas)

5. jaanuaril 2021 sõlmiti AS Merko Ehitus kontserni kuuluva AS Merko Ehitus Eesti ja OÜ Astlanda Ehitus vahel leping betoonitööde teostamiseks Tehnopoli büroohoone ja parkimismaja ehitusel aadressil Mäealuse 2/4, Tallinn.Lepingu raames rajatakse Tallinnas Mustamäe linnaosas asuvasse Tehnopoli teadus- ja ärilinnakusse Tehnopol 3 nime kandva ühe maa-aluse ja kaheksa maapealse korrusega büroohoone ja parkimishoone betoonkonstruktsioonid.Lepingu maksumus on ligikaudu 3,85 miljonit eurot, millele lisandub käibemaks. Tööd valmivad 2021. aasta novembris.AS Merko Ehitus Eesti (merko.ee) on Eesti juhtiv ehitusettevõte, mis teostab üld-, insener-, elektri-, teede- ja elamuehituse töid.Lisainfo: AS Merko Ehitus Eesti betoonitööde osakonna juhataja Risto Sappinen, tel +372 680 5105.Priit RoosimägiFinantsüksuse juhtAS Merko EhitusTelefon: +372 650...

Continue reading

Nabis Holdings Inc. informiert über Umsetzung des Angebots

VANCOUVER, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE:NAB) (OTC:NABIF) (FRA:A2PL) („Nabis“ oder das „Unternehmen“) hat heute bekanntgegeben, dass der zuvor angekündigte Vorschlag des Unternehmens (in der jeweils gültigen Fassung, der „Vorschlag“) im Rahmen des kanadischen Bankruptcy and Insolvency Act, gemäß dem das Unternehmen eine Rekapitalisierung seiner im Umlauf befindlichen unbesicherten, mit 8,0 % verzinsten Wandelschuldverschreibungen in Höhe von 35 Millionen CAD und aller anderen Schuldtitel des Unternehmens vornehmen wird (die „Rekapitalisierung“), voraussichtlich am oder vor dem 31. Januar 2021 umgesetzt wird.Weitere Einzelheiten zu den wesentlichen Bedingungen des Vorschlags sind in den Pressemitteilungen des Unternehmens vom 23. November 2020 und 10. Dezember 2020 enthalten.KSV Restructuring...

Continue reading

The Joint Corp. Acquires Two Regional Developer Territories

SCOTTSDALE, Ariz., Jan. 05, 2021 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, acquired for $2.4 million the regional developer (RD) territories in North Carolina and in Georgia, representing 69 franchised clinics and 37 signed franchise agreements for unopened clinics. The company also acquired a franchised clinic in Scottsdale, where The Joint is headquartered and has strong brand recognition, increasing the number of company-owned or managed clinics to 64 at December 31, 2020.Peter D. Holt, President and Chief Executive Officer of The Joint Corp. said, “Our North Carolina and Georgia RD territories were well run and are now mature markets. When markets reach maturity, it is common for the franchisor to acquire RD rights back, which we did in these cases....

Continue reading

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer, is now available through authorized specialty distributors.“Myovant has been focused on ensuring access to ORGOVYX for men with advanced prostate cancer as quickly as possible following approval, and we are delighted to announce that it is now available,” said David Marek, chief executive officer of Myovant Sciences, Inc. “As part of our commitment to redefine care for women and for men, this is a critical step as we work to bring about...

Continue reading

Brookfield Asset Management Announces Appointment of Hutham Olayan to Board of Directors

BROOKFIELD NEWS, Jan. 05, 2021 (GLOBE NEWSWIRE) — Brookfield Asset Management Inc. (“Brookfield” or the “Corporation”) (TSX: BAM.A, NYSE: BAM) announced today the appointment of Hutham Olayan to its board of directors. Ms. Olayan is Chair of The Olayan Group, a multinational investment enterprise as well as a leading operator of businesses in Saudi Arabia, where the group originated in 1947. Ms. Olayan has decades of experience as a long-term investor in various asset classes in global markets.Frank McKenna, Chair of the Board of Directors of Brookfield, stated, “We are thrilled to welcome Ms. Olayan to Brookfield. As an accomplished business leader and skilled director, she brings vast knowledge and significant experience in international business to the board of directors.” Mr. McKenna continued, “Ms. Olayan’s appointment furthers...

Continue reading

Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET.The live webcast will be available in the investor section of the company’s website at www.beamtx.com. The webcast will be archived for 60 days following the presentation.About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in...

Continue reading

PureGold Appoints Vice President Business Development

VANCOUVER, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — Pure Gold Mining Inc. (PGM:TSX-V, PUR:LSE) (“PureGold” or the “Company”), is pleased to announce the appointment of Chris Haubrich as Vice President, Business Development.Mr. Haubrich is a mining finance professional and registered Professional Mining Engineer with over a decade of experience in mergers and acquisitions, corporate strategy, capital markets, operations, and engineering consulting in the mining industry. Prior to joining PureGold, he served as Vice President, Investment Banking with National Bank Financial where he covered the mining sector and advised clients on a wide range of M&A and financing transactions. Mr. Haubrich started his career as an underground mining engineer with Cameco Corporation and has since evaluated numerous mining projects across...

Continue reading

Probe Metals Intersects 7.3 g/t Au over 10.4 metres on the Monique Mining Lease, Val-d’Or East Project

Highlights:I Zone expansion drilling returned 7.3 g/t Au over 10.4 metres, 2.9 g/t Au over 17.9 metres, 2.4 g/t Au over 10 metres 1.5 g/t Au over 12.8 metres and 1.8 g/t over 11.9 metres, located 300 metres south of the Former Monique open pit Mine, between surface and 200 metres vertical depth.M Zone expansion drilling returned 2.6 g/t Au over 5 metres and 2.3 g/t over 8 metres, located 700 metres southeast of the Former Monique open pit, between surface and 225 metres vertical depth.All results from the 2020 drilling program will be included in the next resource estimate in Q1 2021.The winter 2021 drilling program begins today with four drills in Val-D’Or East.TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Probe Metals Inc. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to provide new results from the 2020...

Continue reading

Probe Metals obtient en forage 7,3 g/t Au sur 10,4 mètres sur le bail minier Monique du projet Val-d’Or Est

Faits saillants :Le forage d’expansion dans la zone I a livré des teneurs de 7,3 g/t Au sur 10,4 mètres, 2,9 g/t Au sur 17,9 mètres, 2,4 g/t Au sur 10 mètres, 1,5 g/t Au sur 12,8 mètres et 1,8 g/t Au sur 11,9 mètres, à 300 mètres au sud de l’ancienne mine à ciel ouvert Monique, entre la surface et une profondeur verticale de 200 mètres.Le forage d’expansion dans la zone M a livré des teneurs de 2,6 g/t Au sur 5 mètres et 2,3 g/t Au sur 8 mètres, à 700 mètres au sud-est de l’ancienne fosse Monique, entre la surface et une profondeur verticale de 225 mètres.Tous les résultats programme de forage d’expansion 2020 seront intégrés dans la prochaine estimation des ressources au T1 2021.Le programme de forage de l’hiver 2021 débute aujourd’hui avec quatre foreuses à Val-d’Or EstTORONTO, 05 janv. 2021 (GLOBE NEWSWIRE) — Probe Metals Inc....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.